Please use this identifier to cite or link to this item: https://hdl.handle.net/10923/11627
Full metadata record
DC FieldValueLanguage
dc.contributor.authorStephen Doral Stefani-
dc.contributor.authorVanessa Teich-
dc.contributor.authorAndré Poisl Fay-
dc.contributor.authorMarcia Abadi-
dc.contributor.authorScott Flanders-
dc.contributor.authorCat Bui-
dc.contributor.authorAndre Sasse-
dc.date.accessioned2018-05-30T14:09:16Z-
dc.date.available2018-05-30T14:09:16Z-
dc.date.issued2015-
dc.identifier.issn2175-2095-
dc.identifier.urihttp://hdl.handle.net/10923/11627-
dc.language.isopt_BR-
dc.relation.ispartofJornal Brasileiro de Economia da Saúde-
dc.rightsopenAccess-
dc.titleCost of preventing an event (COPE) of enzalutamide versus abiraterone plus prednisone in men with metastatic castration-resistant prostate cancer under the Brazilian private health care system perspective-
dc.typeArticle-
dc.date.updated2018-05-30T14:09:15Z-
dc.jtitleJornal Brasileiro de Economia da Saúde-
dc.volume7-
dc.issue3-
dc.spage127-
Appears in Collections:Artigo de Periódico



All Items in PUCRS Repository are protected by copyright, with all rights reserved, and are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. Read more.